VIRAL-BASED IMMUNOTHERAPY FOR THE TREATMENT OF CANCER
InProTher is an immunotherapy company dedicated to developing the world’s first adaptive immune therapy capable of targeting immunosuppressive genes of ancient retroviruses that normally are dormant in the human genome. The retroviral genes are reactivated in cancer and essential for tumor development. InProTher’s proprietary combination of novel technologies is designed to break tolerance to this unique antigen family, thus providing broad anti-cancer efficacy.
We have established a great team of scientists, medical advisors, research assistants, lab assistants etc. with long-standing experience to drive our research every day.